Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer GlobeNewswire - Wed Mar 25, 6:59AM CDT

Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman,...

RXRX : 3.05 (+7.39%)
PacBio Announces the Appointment of Chris Gibson to the Board of Directors GlobeNewswire - Thu Mar 5, 7:30AM CST

MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson,...

PACB : 1.3250 (+5.16%)
RXRX : 3.05 (+7.39%)
Recursion Pharmaceuticals: Q4 Earnings Snapshot AP - Wed Feb 25, 5:38AM CST

Recursion Pharmaceuticals: Q4 Earnings Snapshot

RXRX : 3.05 (+7.39%)
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Wed Feb 25, 5:30AM CST

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical...

RXRX : 3.05 (+7.39%)
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC GlobeNewswire - Mon Feb 23, 7:00AM CST

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in...

RXRX : 3.05 (+7.39%)
Recursion to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Feb 23, 6:55AM CST

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in...

RXRX : 3.05 (+7.39%)
A concept image showing a virus attacking blood cells by crystal light via Shutterstock
Nvidia Dumped Recursion Pharmaceuticals Stock. Should You? Barchart - Thu Feb 19, 3:47PM CST

Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk or opportunity?

NVDA : 174.20 (+5.47%)
RXRX : 3.05 (+7.39%)
ARKK : 67.55 (+6.34%)
MarketBeat.com
NVIDIA’s 13F Bombshell: A New AI Power Trio Emerges MarketBeat - Thu Feb 19, 10:14AM CST

NVIDIA did anything but stand pat with its investments during Q4 2025. See how the company turned over its holdings in the quarter.

NVDA : 174.20 (+5.47%)
CRWV : 76.76 (+11.01%)
INTC : 44.04 (+6.92%)
SNPS : 395.42 (+3.21%)
AMD : 203.29 (+3.70%)
WRD : 8.10 (+13.92%)
APLD : 23.52 (+14.45%)
RXRX : 3.05 (+7.39%)
NBIS : 101.91 (+10.46%)
NOK : 8.01 (+0.63%)
ARM : 150.97 (+10.23%)
AMZN : 209.15 (+4.08%)
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 GlobeNewswire - Wed Feb 18, 7:30AM CST

Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business...

RXRX : 3.05 (+7.39%)
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules GlobeNewswire - Thu Feb 12, 6:59AM CST

Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026,...

RXRX : 3.05 (+7.39%)

Barchart Exclusives

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock? Barchart - 2 minutes ago
Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.